Short answer
Vir Biotechnology, Inc. (VIR) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $240,000 (down 89.9% year over year) with net income of −$163M.
Q3 2025 key financials · XBRL
- Revenue
- $240,000
- −89.9% YoY · −80.2% QoQ
- Net income
- −$163M
- +23.7% YoY · −47.0% QoQ
- Operating margin
- -72267.9%
- EPS (diluted)
- −$1.18
- +24.8% YoY · −47.5% QoQ
Source: XBRL data from the Vir Biotechnology, Inc. (VIR) Q3 2025 10-Q on SEC EDGAR. USD.
Vir Biotechnology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: FDA revoked EUA for sotrovimab COVID-19 treatment December 2024, eliminating expected future US revenue from this product
- Material update: Net loss $395.1M for nine months ended Sept 30, 2025 vs prior $417.4M period; accumulated deficit $1.2B reflects ongoing R&D investment
- Regulatory risk: Potential for FDA and foreign authorities to impose costly additional studies or restrictive labeling even post-approval for product candidates
- Operational risk: Reliance on third parties for clinical supplies and trials creates vulnerability to delays impacting near-term development timelines
- Financial risk: Cash, equivalents, and investments of $810.7M as of Sept 30, 2025 expected to fund at least 12 months, but future capital raising uncertain due to economic and geopolitical instability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vir Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.